Contineum Therapeutics, Inc. Class A Common Stock
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTNM research report →
Companywww.contineum-tx.com
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
- CEO
- Carmine N. Stengone
- IPO
- 2024
- Employees
- 41
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $499.11M
- P/E
- -8.53
- P/S
- 0.00
- P/B
- 1.99
- EV/EBITDA
- -7.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -27.09%
- ROIC
- -26.01%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-59,978,000 · -41.93%
- EPS
- $-2.17 · -33.13%
- Op Income
- $-68,059,000
- FCF YoY
- -66.50%
Performance & Tape
- 52W High
- $16.33
- 52W Low
- $3.35
- 50D MA
- $13.24
- 200D MA
- $12.05
- Beta
- 0.89
- Avg Volume
- 277.32K
Get TickerSpark's AI analysis on CTNM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Lorrain Daniel S. | sell | 3,870 |
| May 1, 26 | Lorrain Daniel S. | sell | 300 |
| Apr 6, 26 | Lorrain Daniel S. | sell | 4,170 |
| Mar 2, 26 | Lorrain Daniel S. | sell | 4,170 |
| Mar 2, 26 | Watkins Tim | other | 3,611 |
| Mar 2, 26 | Watkins Tim | other | 3,611 |
| Mar 2, 26 | Watkins Tim | sell | 3,611 |
| Feb 24, 26 | Stengone Carmine N. | other | 4,400 |
| Feb 25, 26 | Stengone Carmine N. | other | 2,700 |
| Feb 24, 26 | Stengone Carmine N. | other | 4,400 |
Our CTNM Coverage
We haven't published any research on CTNM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CTNM Report →